A Phase 4 interventional study of Tofacitinib with methotrexate and Tofacitinib without methotrexate in Rhematoid Arthritis, sponsored by Pfizer. Completed at 215 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib with methotrexate
Drug: Tofacitinib without methotrexate
Biological: Adalimumab with methotrexate
Drug pages: Tofacitinib · Methotrexate
Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Drug pages: Adalimumab · Methotrexate
Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
Time frame: Month 6
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.
Time frame: Month 6
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (millimeters \[mm\]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and less than (\<) 2.6 indicates remission.
Time frame: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and \<2.6 indicates remission.
Time frame: Month 6
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).
Time frame: Month 6
Percentage of Participants Achieving SDAI ≤3.3 at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.
Time frame: Month 6
Percentage of Participants Achieving CDAI ≤2.8 at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) \<2.6 indicates disease remission.
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) \<2.6 indicates remission.
Time frame: Month 6
Percentage of Participants Achieving SDAI ≤11 at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity.
Time frame: Month 6
Percentage of Participants Achieving CDAI ≤10 at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity.
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.
Time frame: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Time frame: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Time frame: Month 6
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Month 6
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.
Time frame: Month 6
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.
Time frame: Month 6
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.
Time frame: Month 6
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.
Time frame: Month 6
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Time frame: Month 6
| Milestone | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Started | 384 | 376 | 386 |
| Completed | 315 | 303 | 312 |
| Not completed | 69 | 73 | 74 |
| Withdrew: Lack of efficacy | 10 | 3 | 7 |
| Withdrew: Lost to follow-up | 2 | 7 | 3 |
| Withdrew: No longer meets eligibility criteria | 0 | 2 | 0 |
| Withdrew: No longer willing to participate | 6 | 8 | 10 |
| Withdrew: Other | 5 | 6 | 3 |
| Withdrew: Protocol violation | 9 | 9 | 4 |
| Withdrew: Pregnancy | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 11 | 11 |
| Withdrew: Adverse event | 21 | 26 | 36 |
| Withdrew: Death | 2 | 0 | 0 |
ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6 | 38.28 | 46.01 | 43.78 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6 | -23.7 ± 0.62 | -26.6 ± 0.62 | -25.6 ± 0.62 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6 | -22.9 ± 0.61 | -25.5 ± 0.61 | -24.8 ± 0.61 |
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (millimeters \[mm\]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and less than (\<) 2.6 indicates remission.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6 | -2.1 ± 0.07 | -2.5 ± 0.07 | -2.3 ± 0.07 |
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and \<2.6 indicates remission.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6 | -2.1 ± 0.07 | -2.4 ± 0.07 | -2.4 ± 0.07 |
To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6 | 7.54 | 8.67 | 9.58 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving SDAI ≤3.3 at Month 6 | 10.64 ± 0.62 | 13.91 ± 0.62 | 14.37 ± 0.62 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving CDAI ≤2.8 at Month 6 | 10.89 | 14.70 | 14.57 |
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) \<2.6 indicates disease remission.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6 | 11.33 | 12.79 | 13.58 |
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) \<2.6 indicates remission.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6 | 22.69 | 32.75 | 30.17 |
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving SDAI ≤11 at Month 6 | 46.78 ± 0.62 | 53.33 ± 0.62 | 51.15 ± 0.62 |
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving CDAI ≤10 at Month 6 | 45.53 | 52.45 | 50.00 |
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6 | 22.10 | 28.49 | 29.77 |
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6 | 44.54 | 49.57 | 50.86 |
ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6 | 70.06 | 79.13 | 77.65 |
ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6 | 19.66 | 27.11 | 22.64 |
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.
| Units on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6 | -0.52 ± 0.031 | -0.58 ± 0.031 | -0.54 ± 0.031 |
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.
| Percentage of participants | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6 | 71.07 | 75.57 | 72.86 |
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6 | 6.7 ± 0.44 | 7.9 ± 0.43 | 7.8 ± 0.43 |
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6 | 5.2 ± 0.52 | 5.7 ± 0.51 | 4.4 ± 0.51 |
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6 | 6.4 ± 0.52 | 7.3 ± 0.52 | 7.3 ± 0.52 |
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6 | 6.7 ± 0.47 | 7.0 ± 0.47 | 6.3 ± 0.47 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6 | 8.2 ± 0.48 | 10.3 ± 0.48 | 9.9 ± 0.48 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6 | 5.1 ± 0.44 | 6.3 ± 0.44 | 5.4 ± 0.44 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6 | 5.6 ± 0.48 | 6.1 ± 0.47 | 5.7 ± 0.47 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6 | 6.3 ± 0.52 | 7.2 ± 0.52 | 6.2 ± 0.52 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6 | 6.7 ± 0.58 | 7.7 ± 0.58 | 6.0 ± 0.58 |
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.
| Score on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6 | 5.3 ± 0.52 | 5.5 ± 0.52 | 5.0 ± 0.52 |
The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.
| Percentage of impairment | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Work hours missed due to problems | -2.62 ± 0.717 | -2.19 ± 0.700 | -1.75 ± 0.741 |
| Work hours missed other reason | 0.14 ± 1.019 | 0.43 ± 0.991 | -0.77 ± 1.059 |
| Hours worked in past 7 days | 4.13 ± 1.729 | -0.82 ± 1.672 | 1.28 ± 1.788 |
| Problems affecting productivity | -1.94 ± 0.228 | -2.14 ± 0.224 | -1.95 ± 0.232 |
| Problem affecting daily activities | -2.24 ± 0.137 | -2.47 ± 0.138 | -2.24 ± 0.139 |
| % work time missed due to health | -4.51 ± 1.790 | -3.41 ± 1.794 | -1.87 ± 1.831 |
| % impairment while working due to health | -19.38 ± 2.276 | -21.44 ± 2.235 | -19.52 ± 2.320 |
| % overall work impairment due to health | -20.16 ± 2.663 | -22.27 ± 2.638 | -21.87 ± 2.710 |
| % activity impairment due to health | -22.36 ± 1.375 | -24.74 ± 1.383 | -22.45 ± 1.394 |
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.
| Units on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Utility score | 0.20 ± 0.013 | 0.22 ± 0.013 | 0.22 ± 0.013 |
| Mobility score | -0.29 ± 0.027 | -0.26 ± 0.027 | -0.28 ± 0.027 |
| Self-care score | -0.27 ± 0.028 | -0.33 ± 0.028 | -0.32 ± 0.028 |
| Usual activities score | -0.24 ± 0.029 | -0.26 ± 0.029 | -0.30 ± 0.029 |
| Pain/discomfort score | -0.32 ± 0.026 | -0.34 ± 0.026 | -0.37 ± 0.026 |
| Anxiety/depression score | -0.21 ± 0.029 | -0.24 ± 0.029 | -0.22 ± 0.029 |
| VAS score | 20.84 ± 1.100 | 20.98 ± 1.100 | 19.61 ± 1.100 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
| Units on a scale | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6 | 7.14 ± 0.500 | 7.59 ± 0.498 | 6.07 ± 0.499 |
Collected over SAEs were assessed from informed consent up to at least 28 calendar days after last dose of investigational product. AEs were recorded from the time the subject has taken at least one dose of study treatment through last subject visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID | — | 35/384 (9.1%) | 51/384 (13.3%) |
| Tofacitinib 5 mg BID + MTX | — | 27/376 (7.2%) | 72/376 (19.1%) |
| Adalimumab 40 mg + MTX | — | 24/386 (6.2%) | 69/386 (17.9%) |
| Event | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Hip fractureInjury, poisoning and procedural complications | 0/384 | 3/376 | 0/386 |
| CellulitisInfections and infestations | 3/384 | 1/376 | 0/386 |
| PyelonephritisInfections and infestations | 0/384 | 2/376 | 0/386 |
| Chest painGeneral disorders | 2/384 | 1/376 | 1/386 |
| CholelithiasisHepatobiliary disorders | 2/384 | 0/376 | 1/386 |
| PyrexiaGeneral disorders | 0/384 | 0/376 | 2/386 |
| Renal colicRenal and urinary disorders | 0/384 | 0/376 | 2/386 |
| PancytopeniaBlood and lymphatic system disorders | 0/384 | 1/376 | 0/386 |
| Myocardial ischaemiaCardiac disorders | 0/384 | 1/376 | 0/386 |
| Necrotising retinitisEye disorders | 0/384 | 1/376 | 0/386 |
| Event | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 25/384 | 37/376 | 29/386 |
| Alanine aminotransferase increasedInvestigations | 8/384 | 23/376 | 26/386 |
| NasopharyngitisInfections and infestations | 22/384 | 16/376 | 18/386 |
| Age, Continuous(Years) | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX | Total |
|---|---|---|---|---|
| Mean | 49.7 ± 12.2 | 50.0 ± 13.4 | 50.7 ± 13.4 | 50.1 ± 13.0 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID | Tofacitinib 5 mg BID + MTX | Adalimumab 40 mg + MTX | Total |
|---|---|---|---|---|
| Female | 319 | 311 | 320 | 950 |
| Male | 65 | 65 | 66 | 196 |
Showing the first 100 of 215 sites across 25 countries. Choose a country and city above to see the rest.
Ran from Aug 2014 to primary completion in Dec 2016, 28 months.
Results were first posted in Jun 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tofacitinib · Methotrexate